Table 1.

Selected studies with platinum salts in gBRCA1/2m breast cancer

Study	Disease		Phase	Total (n)	BRCAm (n)	TNBC (n)	BRCAm ER+ (n)		Treatment	Response in overall population	Response in patients with wtBRCA1/2		Response in patients with gBRCA1/2m	Response in patients with BRCA1m
Advanced and metastatic breast cancer
TNT45	Metastatic TNBC or BRCA1/2 mutation BC		III	376	43	363	12		Carboplatin vs docetaxel	ORR: 31% with carboplatin vs 36% with docetaxel	NR		68% with carboplatin vs 33% with docetaxel	NR
TBCRC00948	Metastatic TNBC		II	86	11	86	0		Cisplatin or carboplatin	ORR: 25.6% (22/86)	ORR: 19.7% (13/66)		ORR: 54.5% (6/11)	NR
NCT0161172747	Metastatic BC with a BRCA1 mutation		II	20	20a	14	5		Cisplatin	NR	NR		NR	ORR: 80% CR: 45%
Brocade 2 NCT0150660982	Locally recurrent or metastatic BC with a gBRCA1/2 mutation		II	99	99	42	56 (ER+ and/or PgR+)		Paclitaxel/carboplatin/placebo (PCP)	61%	NR		61%	NR
Early-stage disease
NCT0163022685		Stage I–III BC with a BRCA1 mutation	II	107	107b	82		16	Cisplatin	NR		NR	NR	pCR: 61%
GeparSixto/GBG 66 NCT0142688087,88		Stage I–III TNBC or HER2+ BC	II/III	588	50	315 291 BRCA known		0	Backbone regimen ± carboplatin	With vs without carboplatin: TNBC pCR: 53% vs 37% 291 BRCA known status: 57% vs 41%		With vs without carboplatin: TNBC pCR: 55% vs 36%	With vs without carboplatin: TNBC pCR: 65% vs 67%	NR

BC breast cancer, CR complete response, ER+ oestrogen receptor-positive, gBRCA1/2 germline BRCA1/2, HER2+ human epidermal growth factor receptor 2-positive, NR not reported, ORR overall response rate, pCR pathologic complete response, PgR+ progesterone receptor-positive, TNBC triple-negative breast cancer, wtBRCA1/2 wild-type BRCA1/2

^aAll were HER2-negative, 15 were ER-negative, 17 were PgR-negative, and 14 were TNBC

^b100 were HER2-negative (5 HER2 status unknown), 86 were ER-negative (5 ER status unknown), 91 were PgR-negative (6 PgR status unknown), and 82 were TNBC